Anti-SARS-CoV-2 RBD-01 Humanized Antibody | A2353

The spike (S) glycoprotein of coronaviruses mediates entry into receptor-expressing host cells and plays the most important role in viral attachment, fusion, and entry; therefore, it serves as an important target for monoclonal antibodies, entry inhibitors, and vaccines. The S protein has two domains S1 and S2, where S1 facilitates initial binding to the receptor and the S2 domain drives membrane fusion and eventual entry of the virus. Within the S1 protein, the highly conserved receptor-binding domain (RBD) expresses a high affinity for the Angiotensin converting enzyme 2 receptor (ACE2). The original biosimilar was designed to target the RBD at different epitopes in tandem with Anti-SARS-CoV-2 RBD-02 (Cat. No. A2354) in order to reduce drug resistance during COVID-19 therapeutic trials.

A2353 | Anti-SARS-CoV-2 RBD-01 Humanized Antibody DataSheet

Antibody Target: Receptor binding domain of SARS-CoV-2 spike protein

Target Alternative Name: COVID-19 Spike RBD protein; 2019-nCoV Spike RBD protein

Tag Line: A humanized monoclonal antibody targeting the SARS-CoV-2 spike protein receptor binding domain, in tandem with Anti-SARS-CoV-2 RBD-02

Category: GM-CSF

Host: XtenCHO cells

Isotype: Humanized IgG1

Species Reactivities: SARS-CoV-2

Immunogen Sequence: Receptor binding domain of SARS-CoV-2 spike protein

Accession #:

Gene ID:

Appearance: Liquid

Form: Humanized IgG1

Concentration:

Formulation: In PBS, pH 7.5

Purification:

Application: ELISA

Positive Control:

Application And Usages:

Country of Animal Origin: USA

Country of Manufacture: USA

Usage: For Research Use Only! Not to be used in humans.

Handling: The antibody solution should be gently mixed before use.

Western Blot Verified: TRUE

Immunocytochemistry Verified: FALSE

Immunofluorescence Verified: FALSE

Immunoprecipitation Verified: FALSE

FACS Verified: FALSE

ELISA Verified: FALSE

ChIP Verified: FALSE

Dot Blot Verified: FALSE

Flow Cytometry Verified: FALSE